Initiator Pharma has internally investigated pudafensine and IP2018 in preclinical models for Female Sexual Dysfunction (FSD). Significant efficacy has been shown in the animal FSD models that are highly relevant and offer a way to predict efficacy in the clinical setting.
Based on these promising findings, the board and leadership team are reviewing the potential for extending the previous efforts in male erectile dysfunction (ED) also to include FSD. The strategic review will include the data generated to establish the best development plan, positioning and commercialization strategy for the asset going forward. The review will be executed in Q4, 2023, from both a commercial and clinical perspective, to best capture and optimize the large potential value offered.